Safety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
Open Access
- 28 November 2012
- journal article
- Published by Wiley in Journal of Diabetes
- Vol. 4 (4) , 395-406
Abstract
The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. Data from 3556 patients treated with once-daily MXR for 12 weeks, or until discontinuation, were analyzed. Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) side-effects and only 0.7% of patients discontinued for this reason (primary endpoint). The incidence of GI side-effects and related discontinuations appeared to be considerably lower during short-term MXR therapy than during previous treatment (mean 2.71 years' duration), most commonly with immediate-release metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose levels from baseline. The present study provides new insights into the incidence of GI side-effects with MXR in Asian patients with T2DM and on the tolerability of MXR in non-Caucasian populations. Specifically, these data indicate that once-daily MXR not only improves measures of glycemic control in Asian patients with T2DM, but also has a favorable GI tolerability profile that may help promote enhanced adherence to oral antidiabetic therapy.Keywords
This publication has 33 references indexed in Scilit:
- Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population‐based studyDiabetes, Obesity and Metabolism, 2009
- The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre studyInternational Journal Of Clinical Practice, 2008
- Obesity and Diabetes in the Developing World — A Growing ChallengeNew England Journal of Medicine, 2007
- Steady-State Pharmacokinetics of a Novel Extended-Release Metformin FormulationClinical Pharmacokinetics, 2005
- Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort studyCurrent Medical Research and Opinion, 2004
- Overcoming the barriers to effective glycaemic control for type 2 diabetesBritish Journal of Diabetes, 2002
- Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetesBritish Journal of Diabetes, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM PatientsDiabetes Care, 1993
- Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 1993